Deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray
- PMID: 37573504
- PMCID: PMC10448413
- DOI: 10.1016/j.xpro.2023.102509
Deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray
Abstract
Here, we present a protocol for deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray. We describe steps for utilizing NMF-defined group 3/group 4 metagenes to calculate a continuum score between 0 and 1 that can be projected onto new sample data analyzed via RNA-sequencing. We then detail procedures for reverse engineering a continuum score for samples analyzed via DNA methylation microarray using a random forest classifier.
Keywords: Bioinformatics; Cancer; Molecular Biology; RNAseq; Sequence analysis; Sequencing.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Figures
References
-
- Williamson D., Schwalbe E.C., Hicks D., Aldinger K.A., Lindsey J.C., Crosier S., Richardson S., Goddard J., Hill R.M., Castle J., et al. Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development. Cell Rep. 2022;40 - PMC - PubMed
-
- Venables W.N., Ripley B.D. Springer; 2002. Modern Applied Statistics with S. ISBN 0-387-95457-0.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
